The safety and efficacy of Futibatinib are now being compared with standard of care (gemcitabine-cisplatin) in a multicenter phase 3 study of patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements (NCT04093362). Here, FGFR2 is linked to cholangiocarcinoma.